In a 69-year-old woman with stable schizoaffective disorder who is currently taking olanzapine 10 mg at bedtime, what non‑antipsychotic medications can be used?

Non-Antipsychotic Medications for Stable Schizoaffective Disorder on Olanzapine

For a stable 69-year-old woman with schizoaffective disorder on olanzapine 10 mg, you should add metformin 500-850 mg twice daily to mitigate metabolic side effects, and consider antidepressants (SSRIs/SNRIs) if depressive symptoms persist, or mood stabilizers (lithium or valproate) if mood instability remains problematic.

Metabolic Protection: First Priority

Since your patient is on olanzapine, which has the worst cardiometabolic profile among antipsychotics, metformin should be offered concomitantly 1. The 2025 INTEGRATE guidelines specifically recommend metformin with olanzapine to attenuate weight gain 1. This is particularly important in a 69-year-old patient where metabolic complications carry higher morbidity and mortality risks.

• Dosing: Start metformin 500 mg once or twice daily, titrate to 850 mg twice daily as tolerated
• Monitoring: Check renal function before starting; avoid if renal failure present 1
• Rationale: Prevents the substantial weight gain and metabolic syndrome that olanzapine commonly causes

Addressing Residual Symptoms

For Persistent Depressive Symptoms

Antidepressant augmentation can be beneficial even without a formal depression diagnosis 1. The guidelines note that antidepressants may improve negative symptoms in schizoaffective disorder, though benefits may be modest 1.

• Options: SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine, duloxetine)
• Caution: Monitor for pharmacokinetic interactions and serotonin syndrome risk 1
• Evidence: Antidepressant augmentation improved negative and total symptoms in treatment-resistant cases (g = -0.74 for negative symptoms, g = -0.69 for total symptoms) 2

For Mood Instability (Bipolar-Type Schizoaffective)

If your patient has the bipolar subtype with residual mood instability, mood stabilizers are appropriate adjuncts:

• Lithium or valproate: These are the standard mood stabilizers used in combination with antipsychotics for schizoaffective disorder 3
• Evidence: Augmentation studies with mood stabilizers showed success in well-designed trials 4

For Persistent Negative Symptoms

Before adding medications, rule out secondary causes 1:

• Persistent positive symptoms
• Depressive symptoms (treat with antidepressants as above)
• Medication side effects (extrapyramidal symptoms, sedation)
• Medical illness (hypothyroidism, sleep apnea from weight gain)
• Social isolation

If negative symptoms persist after addressing these:

• Consider antidepressant augmentation as discussed above 1
• Psychosocial interventions should be offered to encourage social engagement 1

What NOT to Add

Do not add another antipsychotic unless the patient is treatment-resistant with persistent positive symptoms. The guidelines are clear that antipsychotic augmentation should only occur after failed adequate trials of monotherapy 1. Your patient is stable, so this doesn't apply.

Monitoring Strategy

For a 69-year-old on olanzapine with added non-antipsychotic medications:

• Metabolic parameters: Weight, waist circumference, fasting glucose, lipids every 3 months initially
• Renal function: If on metformin, monitor creatinine periodically
• Drug interactions: Be vigilant for serotonergic interactions if using antidepressants
• Mood and psychotic symptoms: Regular assessment to ensure stability is maintained

Clinical Pitfalls to Avoid

1. Don't assume stability means no intervention needed: Metabolic protection with metformin is preventive medicine that reduces long-term morbidity and mortality
2. Don't overlook subsyndromal depressive symptoms: These significantly impact quality of life and respond to antidepressants even without meeting full criteria for major depression
3. Don't add multiple medications simultaneously: Introduce one agent at a time to assess tolerability and efficacy
4. Don't forget that schizoaffective disorder has both psychotic AND mood components: The mood component may require specific treatment beyond the antipsychotic

The evidence base for schizoaffective disorder is limited compared to schizophrenia 3, but the principles from recent schizophrenia guidelines 1 combined with specific schizoaffective studies 3 support this algorithmic approach prioritizing metabolic protection and targeted treatment of residual mood symptoms.